# US 2024/0197750 A1 · Ceftibuten dosing regimens

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0197750 A1
- Document ID: US20240197750A1
- Status: Published application
- Kind: A1
- Application number: 18/553,769
- Filed: 2022-03-31
- Published: 2024-06-20
- Earliest claimed: 2021-04-05
- Assignees: Qpex Biopharma, Inc.
- Applicants: QPEX Biopharma, Inc.
- Inventors: David C. Griffith; Olga Lomovskaya; Elizabeth E. Morgan; Jeffery S. Loutit
- Web page: https://patentgrep.com/patent/US20240197750A1

## CPC

- A61K 31/546: containing further heterocyclic rings, e.g. cephalothin
- A61P 31/04: Antibacterial agents
- A61K 31/423: condensed with carbocyclic rings
- A61K 31/424: condensed with heterocyclic ring systems, e.g. clavulanic acid
- A61K 31/431: containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
- A61K 31/551: having two nitrogen atoms, e.g. dilazep
- A61K 31/69: Boron compounds
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed herein are dosing regimens of ceftibuten in combination with a β-lactamase inhibitor. The dosing regimens include ceftibuten at a dose higher than 400 mg per day (for example, 400 mg BID, 600 mg QD or BID, or 800 mg QD or BID).

## Claims

### Claim 1

A pharmaceutical composition, comprising:
ceftibuten in an amount greater than 400 mg; and
a β-lactamase inhibitor.

### Claim 2 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 500 mg.

### Claim 3 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 550 mg.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 600 mg.

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 650 mg.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 700 mg.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount greater than 750 mg.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount of about 600 mg.

### Claim 9 (depends on 1)

The pharmaceutical composition of claim 1, wherein ceftibuten is present in an amount of about 800 mg.

### Claim 10 (depends on 1)

The pharmaceutical composition of claim 1, wherein the β-lactamase inhibitor is a compound having the structure of any one of Formulas (I)-(IX):
or pharmaceutically acceptable salts thereof, wherein:
each R1 is independently a C1-6 alkyl, or each R1 together with the geminal carbon atom to which they are bonded forms an optionally substituted C3-6 cycloalkyl ring or an optionally substituted 4-6 membered heterocycloalkyl ring;
R2 is selected from a single bond, optionally substituted C1-6 alkyl, optionally substituted 2-6 membered heteroalkyl, optionally substituted C5-6 cycloalkyl, optionally substituted 5-6 membered heterocycloalkyl, optionally substituted phenyl, and optionally substituted 5-6 membered heteroaryl;
R3 is selected from C1-6 alkyl, —O—C(O)—R4, —S—C(O)—R4, —NH—C(O)—R4, —O—C(O)—O—R4, —S(O)—O—R4, —NH—C(O)—O—R4, —(O)—O—R4, —C(O)—S—R4, —C(O)—NH—R4, —O—(O)—O—R4, —O—C(O)—S—R4, —O—C(O)—NH—R4, —S—S—R4, —S—R4, —NH—R4, and —CH(—NH2)—R4);
R4 is selected from hydrogen, optionally substituted C1-8 alkyl, optionally substituted 2-8 membered heteroalkyl, optionally substituted C5-8 cycloalkyl, optionally substituted 5-8 membered heterocycloalkyl, optionally substituted C5-10 cycloalkylalkyl, optionally substituted 5-8 membered heterocycloalkyl-C1-3-alkyl, optionally substituted phenyl, optionally substituted 5-8 membered heteroaryl, optionally substituted C7-10 arylalkyl, and optionally substituted 5-8 membered heteroaryl-C1-3-alkyl;
R5 is selected from the group consisting of C1-6 alkyl, —NR6R7, —CH2C(O)NH2, and
and
R6 and R7 are independently selected from the group consisting of H, C1-6 alkyl, and —CH2C(O)NH2.

### Claim 11 (depends on 1)

The pharmaceutical composition of claim 1, wherein the β-lactamase inhibitor is a compound having the structure of any one of Formulas (X)-(XVII):
or pharmaceutically acceptable salts thereof, wherein:
R8 is selected from the group consisting of C1-9 alkyl, —CR10R11OC(O)C1-9alkyl, —CR10R11OC(O)C3-7carbocyclyl, —CR10R11OC(O)(3 to 7 membered heterocyclyl), —CR10R11OC(O)C2-8alkoxyalkyl, —CR1OR11OC(O)OC1-9alkyl, —CR10R11OC(O)OC3-7carbocyclyl, —CR10R11OC(O)O(3 to 7 membered heterocyclyl), —CR10R11OC(O)OC2-8alkoxyalkyl, —CR10R11OC(O)C6-10aryl, —CR10R11OC(O)OC6-10aryl, —CR10R11C(O)NR13R14, —CR10R11OC(O)O(CH2)1-3C(O)NR13R14, —CR10R11OC(O)O(CH2)2-3OC(O)C1-4 alkyl, —CR10R11OC(O)O(CH2)1-3C(O)OC1-4 alkyl, —CR10R11OC(O)(CH2)1-3OC(O)C1-4 alkyl, and
each R10 and R11 is independently selected from the group consisting of H, optionally substituted C1-4alkyl, optionally substituted C3-7 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10aryl, and optionally substituted 5-10 membered heteroaryl;
each R13 and R14 is independently selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C3-7 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10aryl, and optionally substituted 5-10 membered heteroaryl; and
R15 is optionally substituted C1-6 alkyl.

### Claim 12 (depends on 1)

The pharmaceutical composition of claim 1, wherein the β-lactamase inhibitor is selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 13

A method of treating a bacterial infection, comprising co-administering to a subject in need thereof ceftibuten in an amount greater than 400 mg and a β-lactamase inhibitor.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 500 mg.

### Claim 15 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 550 mg.

### Claim 16 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 600 mg.

### Claim 17 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 650 mg.

### Claim 18 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 700 mg.

### Claim 19 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount greater than 750 mg.

### Claim 20 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount of about 600 mg.

### Claim 21 (depends on 13)

The method of claim 13, wherein the ceftibuten is administered in an amount of about 800 mg.

### Claim 22 (depends on 13)

The method of claim 13, wherein the β-lactamase inhibitor is a compound having the structure of any one of Formulas (I)-(IX):
or pharmaceutically acceptable salts thereof, wherein:
each R1 is independently a C1-6 alkyl, or each R1 together with the geminal carbon atom to which they are bonded forms an optionally substituted C3-6 cycloalkyl ring or an optionally substituted 4-6 membered heterocycloalkyl ring;
R2 is selected from a single bond, optionally substituted C1-6 alkyl, optionally substituted 2-6 membered heteroalkyl, optionally substituted C5-6 cycloalkyl, optionally substituted 5-6 membered heterocycloalkyl, optionally substituted phenyl, and optionally substituted 5-6 membered heteroaryl;
R3 is selected from C1-6 alkyl, —O—C(O)—R4, —S—C(O)—R4, —NH—C(O)—R4, —O—C(O)—O—R4, —S(O)—O—R4, —NH—C(O)—O—R4, —(O)—O—R4, —C(O)—S—R4, —C(O)—NH—R4, —O—(O)—O—R4, —O—C(O)—S—R4, —O—C(O)—NH—R4, —S—S—R4, —S—R4, —NH—R4, and —CH(—NH2)—R4);
R4 is selected from hydrogen, optionally substituted C1-8 alkyl, optionally substituted 2-8 membered heteroalkyl, optionally substituted C5-8 cycloalkyl, optionally substituted 5-8 membered heterocycloalkyl, optionally substituted C5-10 cycloalkylalkyl, optionally substituted 5-8 membered heterocycloalkyl-C1-3-alkyl, optionally substituted phenyl, optionally substituted 5-8 membered heteroaryl, optionally substituted C7-10 arylalkyl, and optionally substituted 5-8 membered heteroaryl-C1-3-alkyl;
R5 is selected from the group consisting of C1-6 alkyl, —NR6R7, —CH2C(O)NH2, and
and
R6 and R7 are independently selected from the group consisting of H, C1-6 alkyl, and —CH2C(O)NH2.

### Claim 23 (depends on 13)

The method of claim 13, wherein the β-lactamase inhibitor is a compound having the structure of any one of Formulas (X)-(XVII):
or pharmaceutically acceptable salts thereof, wherein:
R8 is selected from the group consisting of C1-9 alkyl, —CR10R11OC(O)C1-9alkyl, —CR10R11OC(O)C3-7carbocyclyl, —CR10R11OC(O)(3 to 7 membered heterocyclyl), —CR10R11OC(O)C2-8alkoxyalkyl, —CR10R11OC(O)OC1-9alkyl, —CR10R11OC(O)OC3-7carbocyclyl, —CR10R11OC(O)O(3 to 7 membered heterocyclyl), —CR10R11OC(O)OC2-8alkoxyalkyl, —CR10R11OC(O)C6-10aryl, —CR10R11OC(O)OC6-10aryl, —CR10R11C(O)NR13R14, —CR10R11OC(O)O(CH2)1-3C(O)NR13R14, —CR10R11OC(O)O(CH2)2-3OC(O)C1-4 alkyl, —CR10R11OC(O)O(CH2)1-3C(O)OC1-4 alkyl, —CR10R11OC(O)(CH2)1-3OC(O)C1-4 alkyl, and
each R10 and R11 is independently selected from the group consisting of H, optionally substituted C1-4alkyl, optionally substituted C3-7 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10aryl, and optionally substituted 5-10 membered heteroaryl;
each R13 and R14 is independently selected from the group consisting of H, optionally substituted C1-6alkyl, optionally substituted C3-7 carbocyclyl, optionally substituted 3-10 membered heterocyclyl, optionally substituted C6-10aryl, and optionally substituted 5-10 membered heteroaryl; and
R15 is optionally substituted C1-6 alkyl.

### Claim 24 (depends on 13)

The method of claim 13, wherein the β-lactamase inhibitor is selected from the group consisting of:
or pharmaceutically acceptable salts thereof.

### Claim 25 (depends on 13)

The method of claim 13, wherein the amount of ceftibuten is administered once a day.

### Claim 26 (depends on 13)

The method of claim 13, wherein the amount ceftibuten is administered twice a day.
